Novartis | NOVN - Trade Creditors


Novartis reported $4.26B in Trade Creditors for its fiscal quarter ending in June of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Alcon AG USD 919M 7M Mar/2026
Almirall EUR 235.53M 22.52M Jun/2026
Amgen USD 2.86B 16.65B Jun/2026
AstraZeneca USD 22.89B 388M Jun/2026
Autolus Therapeutics Ltd USD 1.87M 1.21M Mar/2026
Bayer EUR 6.59B 496M Mar/2026
Biogen USD 403.9M 45.4M Jun/2026
Bristol-Myers Squibb USD 4.16B 76M Jun/2026
Eli Lilly USD 6.11B 1.08B Jun/2026
Fresenius EUR 1.23B 25M Jun/2026
Fresenius Medical Care EUR 890.43M 54.88M Mar/2026
Genmab DKK 116M 110M Jun/2026
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 7M Jun/2026
GRIFOLS EUR 1B 160M Jun/2026
Hikma Pharmaceutical USD 715M 104M Dec/2025
J&J USD 9.22B 1.24B Jun/2026
Lakefront Biotherapeutics EUR 95.77M 8.88M Mar/2026
Lonza CHF 471M 3M Dec/2024
Merck EUR 2.13B 19M Mar/2026
Merck USD 3.83B 36M Jun/2026
Novartis USD 4.26B 64M Jun/2026
Novartis USD 4.32B 134M Mar/2026
Novo Nordisk DKK 14.59B 212M Jun/2026
Orion EUR 109M 41.3M Jun/2026
Pfizer USD 4.58B 75M Jun/2026
Philips EUR 2.08B 90M Jun/2026
Recordati EUR 321.16M 14.26M Jun/2026
Regeneron Pharmaceuticals USD 1.16B 132.2M Jun/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sanofi EUR 23.6B 888M Jun/2026
UCB EUR 4.04B 755M Dec/2025